India Activists Challenge Gilead Patent For Sovaldi Hep C Drug
This article was originally published in PharmAsia News
Executive Summary
Gilead's attempt for an India patent for its Sovaldi (sofosbuvir) hepatitis C drug is being challenged by an activist group, the Initiative for Medicines, Access & Knowledge, on grounds the API is a known compound.